Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma

Sunitinib, a multi-targeted receptor tyrosine kinase inhibitor, is a first-line treatment for metastatic renal cell carcinoma (mRCC) in patients in ‘low’ and ‘intermediate’ Memorial Sloan Kettering Cancer Center and Heng risk groups. Disruptions of hematopoiesis, such as anemia, neutropenia, and thr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kucharz, Jakub, Giza, Agnieszka, Dumnicka, Paulina, Kuzniewski, Marek, Kusnierz-Cabala, Beata, Bryniarski, Pawel, Herman, Roma, Zygulska, Aneta Lidia, Krzemieniecki, Krzysztof
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005381/
https://www.ncbi.nlm.nih.gov/pubmed/27573381
http://dx.doi.org/10.1007/s12032-016-0818-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005381/
https://www.ncbi.nlm.nih.gov/pubmed/27573381
http://dx.doi.org/10.1007/s12032-016-0818-9

Ejemplares similares